Hypertension Clinical Trials

796 recruiting

Understanding Hypertension Clinical Trials

The SPRINT trial, published in 2015, reshaped hypertension management by showing that targeting a systolic blood pressure below 120 mmHg — rather than the then-standard 140 mmHg — reduced cardiovascular events and death by 25%, leading to updated treatment guidelines worldwide. Chlorthalidone, losartan, amlodipine, and essentially every major blood pressure medication in use today was established through clinical trials over the past several decades. Current hypertension trials are now tackling persistent challenges including treatment-resistant hypertension, medication adherence, renal denervation as a device-based alternative, and RNA-based therapies that could control blood pressure for months with a single injection.

Why Consider a Clinical Trial?

Hypertension is the most prevalent modifiable risk factor for heart disease, stroke, kidney disease, and premature death worldwide, affecting nearly half of all adults. While many effective medications exist, real-world blood pressure control rates remain disappointingly low — less than half of treated hypertensive patients achieve their targets. The reasons are multifaceted: some patients require four or more medications to control their blood pressure (resistant hypertension), side effects cause many patients to reduce or stop their medications, and the daily pill burden leads to poor long-term adherence. Clinical trials are actively testing solutions to each of these problems. For patients with resistant hypertension — defined as blood pressure that remains above target despite three optimized medications including a diuretic — clinical trials may offer access to novel mechanisms of action not available through standard prescriptions. Device-based approaches like renal denervation, long-acting injectable medications, and gene-silencing therapies (RNA interference) that could provide months of blood pressure control from a single dose represent genuinely new paradigms in hypertension management. Even for patients with more typical hypertension, trials studying optimized combination pills, digital health interventions for adherence, and community-based management programs may provide meaningful improvements in care.

Frequently Asked Questions

Common questions about Hypertension clinical trials

No. While many novel therapy trials focus on resistant hypertension, there are trials for all stages of hypertension. Some trials study people with newly diagnosed hypertension, comparing first-line treatment strategies. Others focus on preventing hypertension in people with elevated blood pressure that has not yet crossed the diagnostic threshold.

Renal denervation is a minimally invasive catheter procedure that reduces the activity of nerves around the kidney arteries that contribute to high blood pressure. Clinical trials have shown it can lower blood pressure by 5-10 mmHg on average. Side effects are generally related to the catheter procedure itself and are uncommon. Long-term safety data from trials is encouraging, but the procedure is still being studied.

Some trials require a medication washout period so researchers can measure the study intervention's independent effect on blood pressure. This is done under close monitoring with frequent blood pressure checks. Other trials are add-on studies where the new treatment is tested alongside your current medications. The specific requirements will be clearly explained before enrollment.

Trials typically use standardized automated blood pressure measurement protocols to minimize variability. Many trials also require 24-hour ambulatory blood pressure monitoring at defined time points, which provides a more comprehensive picture than office readings alone. Some trials now incorporate home blood pressure monitoring with connected devices that transmit readings to the research team.

Yes. Trials also study lifestyle interventions (structured exercise programs, dietary approaches like DASH), digital health tools for medication adherence, community health worker programs, and device-based treatments like renal denervation. These non-pharmacological trials are important for developing approaches that complement or reduce the need for medication.

Showing 120 of 796 trials

Recruiting
Not Applicable

Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter

Intra-Abdominal Hypertension
Wake Forest University Health Sciences50 enrolled1 locationNCT06876896
Recruiting
Phase 2Phase 3

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

OAG - Open-Angle GlaucomaOHT - Ocular Hypertension
Qlaris Bio, Inc.36 enrolled1 locationNCT07354516
Recruiting
Not Applicable

Randomized Controlled Trial of Two Mobile Health Strategies to Manage Postpartum Hypertension

Hypertension, Pregnancy Induced
Jennifer Lewey, MD, MPH770 enrolled3 locationsNCT07209254
Recruiting
Not Applicable

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

HypertensionHypertension, SystolicHypertension,Essential
Orchestra BioMed, Inc500 enrolled98 locationsNCT06059638
Recruiting
Phase 1

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
China National Center for Cardiovascular Diseases72 enrolled1 locationNCT06554301
Recruiting
Phase 3

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1153 locationsNCT07064473
Recruiting
Not Applicable

Development of Novel Physiological CMR Methods in Health and Disease

Heart FailurePulmonary HypertensionMyocardial Infarction+1 more
Sheffield Teaching Hospitals NHS Foundation Trust135 enrolled1 locationNCT03854071
Recruiting
Not Applicable

Coaching and Navigation by Community Health Workers (CHWs) Through Telehealth for High-risk Hypertension

Hypertension
Weill Medical College of Cornell University3,620 enrolled4 locationsNCT07461415
Recruiting
Not Applicable

OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)

Quality of LifeHypertensionSelf-management+1 more
Case Western Reserve University208 enrolled1 locationNCT05293756
Recruiting
Phase 2

A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Pulmonary Hypertension
Pfizer36 enrolled36 locationsNCT07073820
Recruiting
Phase 2

SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism

HypertensionAtrial Fibrillation (AF)
Huashan Hospital66 enrolled1 locationNCT07482020
Recruiting

Autonomic Regulation of Blood Pressure and Heart Rate During Orthostasis and Exercise in Healthy and Hypertensive Individuals

Autonomic DysfunctionHypertensionOrthostatic Hypotension
University Medical Centre Ljubljana120 enrolled1 locationNCT07482462
Recruiting

Homocysteine and Early Diastolic Dysfunction in Newly Diagnosed Hypertension

Hypertension (HTN)Diastolic DysfunctionHyperhomocysteinemia
Necmettin Erbakan University500 enrolled1 locationNCT07480265
Recruiting

Diabetes and Heart Disease Risk in Blacks

ObesityCardiovascular DiseasesHypertension+1 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)2,000 enrolled1 locationNCT00001853
Recruiting

Natural History of Noncirrhotic Portal Hypertension

Cystic FibrosisTurner SyndromeImmunologic Deficiency Syndrome+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)400 enrolled1 locationNCT02417740
Recruiting

Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders

Pulmonary HypertensionConnective Tissue DiseaseAdult Congenital Heart Disease+1 more
Children's Hospital Medical Center, Cincinnati5,000 enrolled1 locationNCT07477197
Recruiting

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

Pulmonary DiseasePulmonary Hypertension
National Institutes of Health Clinical Center (CC)270 enrolled1 locationNCT01730092
Recruiting

Indicators Affecting PVT Recanalization

CirrhosisPortal Hypertension Related to CirrhosisPortal Vein Thrombosis+1 more
Shanghai Zhongshan Hospital1,500 enrolled1 locationNCT07473375
Recruiting
Phase 3

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

Hypertension, Pulmonary
Actelion280 enrolled43 locationsNCT05179876
Recruiting
Phase 3

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

Pulmonary Hypertension Associated With HFpEF
Tenax Therapeutics, Inc.540 enrolled92 locationsNCT07288398